Istari Oncology
Istari Oncology, Inc.: A clinical-stage biotech firm innovating in immuno-oncology for diverse tumor treatments.
Founded
2014Istari Oncology, Inc.: A clinical-stage biotech firm innovating in immuno-oncology for diverse tumor treatments.
Istari Oncology, Inc. is a clinical-stage biotechnology company founded with the mission to advance novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and various other tumors. The company's core vision is to elevate the standard of cancer care by igniting systemic anticancer responses. Istari's flagship product, Lerapolturev (formerly PVSRIPO), aims to address the limitations of current immune checkpoint inhibitors by overcoming the immunosuppressive tumor microenvironment and enhancing the presence of anticancer T cells.
Notable figures affiliated with Istari Oncology include leading scientists and industry experts in oncology and immunotherapy. The company has garnered attention from prominent investors in the biotech sector, contributing to its research and development efforts. Key achievements include advancing Lerapolturev through clinical trials and demonstrating its potential to revolutionize cancer treatment. Istari Oncology's impact lies in its innovative approach to tackling complex immune system challenges, positioning it as a promising player in the fight against cancer.
Companies similar to Istari Oncology include Irazu Oncology, Revitope Oncology, Immune-Onc Therapeutics and MaveriX Oncology.
Istari Oncology was founded in 2014.
Istari Oncology's headquarters is located in Morrisville, NC, US.
Istari Oncology's most recent funding round was for $43.4M (USD) in April 2021.
As of Apr 22, 2021, Istari Oncology has disclosed funding of $48.5M (USD). Undisclosed round amounts are excluded.
Istari Oncology has 37 employees as of Feb 5, 2024.
MaveriX Oncology
